Efficacy and Safety of the CFTR Potentiator Icenticaftor (QBW251) in COPD: Results from a Phase 2 Randomized Trial.

Steven M RoweIeuan JonesMark T DransfieldNazmul HaqueStephen GleasonKaty A HayesKenneth KulmatyckiDenise P YatesHenry DanahayMartin GoslingDavid J RowlandsSarah S Grant

Published in: International journal of chronic obstructive pulmonary disease (2020)

The CFTR potentiator icenticaftor increased FEV1 versus placebo after 28 days and was associated with improvements in systemic inflammation and sputum bacterial colonization in COPD patients; no improvements in LCI with icenticaftor were observed.

Keyphrases

cystic fibrosis
lung function
chronic obstructive pulmonary disease
end stage renal disease
ejection fraction
newly diagnosed
mycobacterium tuberculosis
prognostic factors
patient reported outcomes
air pollution
study protocol
phase iii